Association Between Circulating Tumor Cells and Prognosis in Patients With Stage III Melanoma With Sentinel Lymph Node Metastasis in a Phase III International Multicenter Trial
Author(s) -
Sojun Hoshimoto,
Tatsushi Shingai,
Donald L. Morton,
Christine Kuo,
Mark B. Faries,
Kelly K. Chong,
David Elashoff,
Hong Wang,
Robert M. Elashoff,
Dave S.�B. Hoon
Publication year - 2012
Publication title -
journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.482
H-Index - 548
eISSN - 1527-7755
pISSN - 0732-183X
DOI - 10.1200/jco.2011.40.0887
Subject(s) - medicine , melanoma , hazard ratio , oncology , biomarker , circulating tumor cell , lymphadenectomy , adjuvant , lymph node , sentinel lymph node , metastasis , cancer , confidence interval , cancer research , breast cancer , biochemistry , chemistry
The outcomes of patients with melanoma who have sentinel lymph node (SLN) metastases can be highly variable, which has precluded establishment of consensus regarding treatment of the group. The detection of high-risk patients from this clinical setting may be helpful for determination of both prognosis and management. We report the utility of multimarker reverse-transcriptase quantitative polymerase chain reaction (RT-qPCR) detection of circulating tumor cells (CTCs) in patients with melanoma diagnosed with SLN metastases in a phase III, international, multicenter clinical trial.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom